Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05405374
Other study ID # BGS-21-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 6, 2022
Est. completion date October 2025

Study information

Verified date August 2023
Source Bioventus LLC
Contact Amanda Doan
Phone (901) 341-2976
Email amanda.doan@bioventus.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this clinical study is to compare OSTEOAMP SELECT Fibers to Infuse Bone Graft, in terms of effectiveness and safety, when used as a bone graft substitute in in skeletally mature patients qualified for 2-lumbar interbody fusion (LIF) by means of an intra-patient control model.


Description:

The current study will collect clinical evidence for OSTEOAMP SELECT in spinal fusion procedures. In particular, the study will explore the use of OSTEOAMP SELECT as part of a lumbar interbody fusion (LIF) procedure of two lumbar motion segments between L2 to S1 in patients suffering from symptomatic degenerative disc disease (DDD), degenerative spondylolisthesis, and/or mild degenerative scoliosis. Effectiveness will be based on the lumbar interbody fusion rate at the index levels assessed by a treatment-blinded independent reviewer at 12 months and 24 months. Safety will be evaluated by documenting the number and nature of all (serious) adverse events that may in any way be related to the surgical procedure or product. The complication rate will be compared to the rate in control populations from literature.


Recruitment information / eligibility

Status Recruiting
Enrollment 101
Est. completion date October 2025
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: - Skeletally mature male or female patient, at least 21 years of age and no more than 80 years of age, inclusive, at the time of surgery; - Has symptomatic degenerative disc disease (DDD) of the lumbosacral spine in two levels (L2 to S1). Lumbar DDD is defined as discogenic back pain with or without radicular symptoms confirmed by patient history and radiographic studies - Has radiographic evidence (e.g. CT, MRI, x-ray, etc.) of degenerative lumbosacral disease including instability up to and including Grade 1 spondylolisthesis at the involved level(s) - Requires fusion (i.e., symptomatic) at 2 adjacent or non-adjacent levels from L2 to S1; - Non-responsive to non-operative treatment (e.g., bed rest, physical therapy, medication,spinal injection, manipulation, and/or TENS) for at least 6 months; - Willing and able to comply with the study protocol (including post-operative clinical and radiographic evaluations and required rehabilitation plan) and able to understand and sign the Informed Consent. Exclusion Criteria: - Previous lumbar spine surgery with the exception of discectomy and/or laminectomy at the target levels. - Lumbar scoliosis >30 degrees. - Documented history of osteoporosis, osteomalacia, Paget's disease or metabolic bone disease - Morbidly obese, as defined by a Body Mass Index (BMI) >40 kg/m2. - Documented history of uncontrolled diabetes mellitus - Presence of active malignancy or prior history of malignancy (non-invasive basal cell carcinoma of the skin is allowed). - Overt or active bacterial infection, either local to surgical space or systemic. - Chronic use of steroids (defined as more than 6 weeks of steroid use within 12 months of surgery, other than episodic use or inhaled corticosteroids) - Co-morbidities, which in the investigator's opinion, precludes the subject from being a surgical candidate. - Autoimmune disease, which in the investigator's opinion, is known to affect bone metabolism or the spine (e.g., spondyloarthropathies, juvenile arthritis, rheumatoid arthritis, Graves' disease, Hashimoto's thyroiditis). - Any endocrine or metabolic disorder, which in the investigator's opinion, is known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta). - History of hypersensitivity and/or allergy to any of the agents used to process OSTEOAMP SELECT, including bacitracin, polymyxin B sulfate, and gentamicin. - Known hypersensitivity or allergy to any components of the study treatments including, but not limited to bone morphogenetic proteins (BMPs); injectable collagen; protein pharmaceuticals (e.g., monoclonal antibodies or gamma globulins); bovine collagen products; and/or instrumentation materials (e.g., titanium, titanium alloy, cobalt chrome,cobalt chrome alloy, or PEEK). - Is a prisoner. - Treatment with an investigational therapy (drug, device, and/or biologic) targeting spinal conditions within 3 months prior to implantation surgery, treatment with any other investigational therapies within 30 days prior to implantation surgery, or such treatment is planned during the 24-month period following implantation of the study treatment. - Pregnant or nursing. Females of child-bearing potential must agree not to become pregnant for the duration of the study. - A history of alcohol and/or drug abuse within 6 months prior to screening or exhibits evidence, in the investigator's opinion, of alcohol/drug abuse at screening. - Current history of heavy nicotine use (e.g. more than 20 cigarettes per day). - Any condition, which in the investigator's opinion, would interfere with the subject's ability to comply with study instructions, which might confound data interpretation.

Study Design


Intervention

Other:
OSTEOAMP
OSTEOAMP SELECT Fibers (derived from human bone allograft) rehydrated with bone marrow aspirate (BMA) and combined with local autogenous graft for use in lumbar interbody fusion of the lumbar spine.
Device:
Infuse
The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2, known as dibotermin alfa) placed on an absorbable collagen sponge (ACS). rhBMP-2 is the active agent in the Infuse Bone Graft component. The ACS is a soft, white, pliable, absorbent implantable matrix for rhBMP-2.

Locations

Country Name City State
United States Austin Neurosurgeons Austin Texas
United States New England Baptist Hospital Boston Massachusetts
United States West Virginia University Morgantown West Virginia
United States Tennessee Orthopaedic Alliance Nashville Tennessee
United States Yale University New Haven Connecticut
United States Orthopaedic Institute of Western Kentucky Paducah Kentucky
United States OrthoVirginia Richmond Virginia
United States Spine Institute of Louisiana Shreveport Louisiana
United States Kansas Joint and Spine Specialists Wichita Kansas

Sponsors (1)

Lead Sponsor Collaborator
Bioventus LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Functional Impairment Derived from the Oswestry Low Back Pain Questionnaire to quantify low back pain and function. Zero is equated with no disability and 100 is the maximum disability possible. 24 Months
Other Back Pain Visual Analogue Scale (VAS) change in back pain from baseline to 24 month follow up assessed at time frames: Pre-Op, 6 weeks, 3 month, 6 month, 12 month, 24 month.
Visual Analogue Scale is rated from 0 - 10 cm (no pain - worst possible pain)
24 Months
Other Leg Pain Visual Analogue Scale (VAS) change in leg pain from baseline to 24 month follow up assessed at time frames: Pre-Op, 6 weeks, 3 month, 6 month, 12 month, 24 month.
Visual Analogue Scale is rated from 0 - 10 cm (no pain - worst possible pain)
24 Months
Primary Fusion Status Radiographic fusion as defined by the Image Review Charter and assessed by an independent core laboratory. 12 Months
Secondary Fusion Status Radiographic fusion as defined by the Image Review Charter and assessed by an independent core laboratory. 24 Months
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Active, not recruiting NCT05114135 - TLIF Osteo3 ZP Putty Study (Also Known as the TOP Fusion Study) N/A
Suspended NCT04735185 - Stem Cells vs. Steroids for Discogenic Back Pain N/A
Withdrawn NCT03223701 - Efficacy of Using Solum IV and BMC With GFC in TLIF Phase 4
Completed NCT04057235 - Retrospective Review of Integrity Implants FlareHawk® for Lumbar Fusion
Not yet recruiting NCT06000319 - Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
Active, not recruiting NCT02969616 - Trinity Elite in Lumbar Fusion
Completed NCT02558621 - New Robotic Assistance System for Spinal Fusion Surgery N/A
Completed NCT02104167 - Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating
Completed NCT00996073 - Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion Phase 2
Completed NCT00965380 - Trinity Evolution in Posterior or Transforaminal Lumbar Interbody Fusion (PLIF/TLIF)
Terminated NCT00974623 - Bone Graft Materials Observational Registry N/A
Completed NCT00758719 - Evaluate Effectiveness of the Biomet Lumbar Spinal Fusion System
Completed NCT00165893 - Comparison of IDD Therapy and Non-surgical Treatment for Low Back Pain Caused by Degenerative Disc Disease Phase 4
Terminated NCT01494493 - Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease N/A
Recruiting NCT04727385 - Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease N/A
Completed NCT04849429 - Intra-discal Injection of Platelet-rich Plasma (PRP) Enriched With Exosomes in Chronic Low Back Pain Phase 1
Recruiting NCT04469387 - Preventive Effect of Limited Decompression on Adjacent Segment Following Posterior Lumbar Interbody Fusion N/A
Recruiting NCT04056520 - Clinical and Radiological Outcomes of Posterior Cervical Fusion With Medtronic Infinity Occipitocervical-Upper Thoracic (OCT) System
Completed NCT04119466 - Stabilizing Training in Degenerative Disc Disease N/A